Christenson SA, Smith BM, Bafadhel M, Putcha N (2022) Chronic obstructive pulmonary disease. Lancet 399(10342):2227–2242. https://doi.org/10.1016/S0140-6736(22)00470-6

Article  PubMed  Google Scholar 

Suissa S, Dell’Aniello S, Ernst P (2012) Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67(11):957–963. https://doi.org/10.1136/thoraxjnl-2011-201518

Article  PubMed  Google Scholar 

Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS (2020) Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J COPD 15:439–460. https://doi.org/10.2147/COPD.S234942

Article  Google Scholar 

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB (2024) Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 390(24):2274–2283. https://doi.org/10.1056/NEJMoa2401304

Article  CAS  PubMed  Google Scholar 

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM (2025) Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: phase 3 randomized trial (BOREAS). Respir Med 236:107846. https://doi.org/10.1016/j.rmed.2024.107846

Article  PubMed  Google Scholar 

Pavord ID, Pavord I, Chapman K, Bafadhel M, Sciurba FC, Bradford ES, Schweiker Harris S, Mayer B, Rubin DB, Yancey SW, Paggiaro P (2021) Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 16:1755–1770. https://doi.org/10.2147/COPD.S294333

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID (2025) Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med 392(17):1710–1720. https://doi.org/10.1056/NEJMoa2413181

Article  CAS  PubMed  Google Scholar 

Savran O, Godtfredsen N, Sørensen T, Jensen C, Ulrik CS (2019) COPD patients prescribed inhaled corticosteroid in general practice: based on disease characteristics according to guidelines? Chron Respir Dis 16:1479973119867949. https://doi.org/10.1177/1479973119867949

Article  PubMed  PubMed Central  Google Scholar